Biocon and Mylan’s Biosimilar Trastuzumab Receives Approval from ANVISA, Brazil Through their Partner Libbs
- Friday, December 29, 2017, 1:30
- Finance
- Add a comment
BENGALURU, India and HERTFORDSHIRE, England and PITTSBURGH and SAO PAULO, Dec. 29, 2017 /PRNewswire/ — Biosimilar Trastuzumab, co-developed by Biocon Ltd. (BSE code: 532523, NSE: BIOCON) and Mylan N.V. (NASDAQ, TASE: MYL), has been approved by ANVISA, the Brazilian regulatory agency, thro…
Source: https://www.prnewswire.com/news-releases/biocon-and-mylans-biosimilar-trastuzumab-receives-approval-from-anvisa-brazil-through-their-partner-libbs-300575985.html
About the Author
adminasapcorp has written 37665 stories on this site.